Investors & Media

Ionis announces positive donidalorsen late-stage clinical progress in HAE

Two-year treatment with donidalorsen in the Phase 2 open label study resulted in consistent, sustained protection from HAE attacks Completed enrollment in the Phase 3 OASIS-HAE study Topline Phase 3 results expected in H1 2024 CARLSBAD, Calif. , June 1, 2023 /PRNewswire/ — Ionis Pharmaceuticals,

Read more
You are now leaving to visit